Ascendis Pharma AS (MEX:ASND1N) Cyclically Adjusted PS Ratio: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ASND1N Ascendis Pharma AS MEX:ASND1N
37 GF Score
Price MXN4,270.00
! 5 Warning Signs
View Full Analysis

What is Ascendis Pharma AS Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Ascendis Pharma AS  (MEX:ASND1N) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Ascendis Pharma AS Cyclically Adjusted PS Ratio Related Terms


Ascendis Pharma AS Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Ascendis Pharma AS's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS Cyclically Adjusted PS Ratio Chart

Ascendis Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ascendis Pharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MEX:ASND1N vs BBIO, JAZZ, EXEL: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Ascendis Pharma AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma AS Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma AS's Cyclically Adjusted PS Ratio falls into.


MEX:ASND1N
37GF Score
Ascendis Pharma AS MEX:ASND1N
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascendis Pharma AS Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Ascendis Pharma AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Ascendis Pharma AS's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=79.677/121.6800*121.6800
=79.677

Current CPI (Mar. 2026) = 121.6800.

Ascendis Pharma AS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.938 100.600 1.135
201609 1.007 100.200 1.223
201612 0.737 100.300 0.894
201703 0.231 101.200 0.278
201706 0.277 101.200 0.333
201709 0.288 101.800 0.344
201712 0.176 101.300 0.211
201803 0.016 101.700 0.019
201806 0.010 102.300 0.012
201809 0.010 102.400 0.012
201812 5.583 102.100 6.654
201903 2.736 102.900 3.235
201906 1.477 102.900 1.747
201909 1.025 102.900 1.212
201912 1.098 102.900 1.298
202003 1.201 103.300 1.415
202006 0.774 103.200 0.913
202009 1.361 103.500 1.600
202012 0.242 103.400 0.285
202103 0.338 104.300 0.394
202106 0.455 105.000 0.527
202109 0.493 105.800 0.567
202112 1.997 106.600 2.280
202203 2.640 109.900 2.923
202206 2.347 113.600 2.514
202209 5.454 116.400 5.701
202212 8.453 115.900 8.875
202303 11.556 117.300 11.988
202306 15.658 116.400 16.368
202309 15.868 117.400 16.446
202312 40.472 116.700 42.199
202403 30.411 118.400 31.253
202406 11.675 118.500 11.988
202409 21.967 118.900 22.481
202412 63.514 118.900 64.999
202503 37.202 120.200 37.660
202506 53.705 120.700 54.141
202509 75.708 121.600 75.758
202512 85.279 121.200 85.617
202603 79.677 121.680 79.677

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ascendis Pharma AS Business Description

Address Tuborg Boulevard 12, Hellerup, DNK, 2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score

Get the complete analysis for MEX:ASND1N

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN4,270.00
Price